<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03671343</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL17_0598</org_study_id>
    <nct_id>NCT03671343</nct_id>
  </id_info>
  <brief_title>Physical Rehabilitation and Chronic Kidney Disease</brief_title>
  <acronym>IMPREPA</acronym>
  <official_title>Impact of Physical Rehabilitation on Sarcopenia Inolder and Chronic Kidney Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Older patients with chronic renal failure suffer from sarcopenia. Loss of muscle function is
      associated with increased morbidity and mortality. Currently few treatment are available. The
      aim of this study is to evaluate the impact of physical rehabilitation in this population on
      muscle performance and quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline distance travelled (in meters) during the 6-minute walking distance (6MWD) test (muscular performance), at 3 months</measure>
    <time_frame>Baseline and 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nutritional parameter: Albuminemia</measure>
    <time_frame>Baseline,3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional parameter: Prealbuminemia</measure>
    <time_frame>Baseline,3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional parameter: Body mass index</measure>
    <time_frame>Baseline,3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional parameter: bioimpedancemetry</measure>
    <time_frame>Baseline,3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength evaluated by Hand Grip strength test</measure>
    <time_frame>Baseline,3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life evaluated by the questionnaire SF-36 (36-item medical outcomes study Short-Form health survey)</measure>
    <time_frame>Baseline,3 and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Sarcopenia</condition>
  <condition>Chronic Kidney Disease</condition>
  <condition>Older</condition>
  <arm_group>
    <arm_group_label>Intervention : Physical rehabilitation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Arm &quot;Physical rehabilitation&quot; will benefit from the implementation of the &quot;Loss of Mobility Prevention&quot; program set up in the Department of Aging Medicine of the Center Hospitalier Lyon Sud (CHLS) of Pr BONNEFOY.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control : optimized medical treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The Arm &quot;Optimized medical treatment&quot; will not benefit from the implementation of the &quot;Loss of Mobility Prevention&quot; program.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Physical rehabilitation</intervention_name>
    <description>It will benefit from an initial and final geriatric assessment, an initial dietary balance and a personalized treatment in physical activities adapted for 3 months by an Educator in Adapted Physical Activities.</description>
    <arm_group_label>Intervention : Physical rehabilitation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  man or woman

          -  age over 70 years

          -  CKD stage 3B, 4 or 5 or a DFG &lt;45ml / min according to CKD-EPI formula

          -  an SPPB (Short Physical Performance Battery test )&lt;10

          -  having received a complete and loyal information and having given his written and
             informed consent.

          -  ability to rehabilitate

        Exclusion Criteria:

          -  Subject not presenting previous inclusion criteria

          -  General condition not compatible for the realization of physical rehabilitation

          -  Patient protected under the terms of the law.

          -  Inability to respect the follow-up of the study for geographical, social or
             psychological reasons.

          -  depression or other psychiatric disorder

          -  Refusal to participate in the study

          -  Absence of affiliation to the social security system

          -  Subject in a exclusion period of an other study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laëtitia KOPPE, MD</last_name>
    <phone>0472678715</phone>
    <phone_ext>+33</phone_ext>
    <email>laetitia.koppe@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service de Médecine du vieillissement, soins de suite et de rééducation, Centre Hospitalier Lyon SUd</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marc BONNEFOY, MD</last_name>
      <phone>0472863704</phone>
      <phone_ext>+33</phone_ext>
      <email>marc.bonnefoy@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Marc BONNEFOY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Néphrologie, Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laëtitia KOPPE, MD</last_name>
      <phone>0472678715</phone>
      <phone_ext>+33</phone_ext>
      <email>laetitia.koppe@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Laëtitia KOPPE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis FOUQUE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathilde NOUVIER, Md</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>October 10, 2017</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2018</study_first_posted>
  <last_update_submitted>September 13, 2018</last_update_submitted>
  <last_update_submitted_qc>September 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sarcopenia</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>older</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

